Avastin non-inferior to Eylea in Phase III CRVO trial

NIH’s National Eye Institute (NEI) and colleagues reported that intravitreal Avastin bevacizumab (RG435) was non-inferior to Eylea aflibercept on the primary endpoint of mean change in visual acuity in the participant-blind, U.S. Phase III SCORE2 trial to treat central retinal vein occlusion (CRVO). Specifically, Avastin improved mean visual acuity from baseline to 6 months by 18.6 letters vs. 18.9 letters for Eylea (p=0.001 for non-inferiority). The non-inferiority margin was 5 letters.

Eylea did lead to a greater rate of complete resolution of macular edema compared to Avastin at 6 months (54% vs. 29%), but the researchers said the lower rate in the Avastin arm did not translate to poorer visual acuity outcomes. The incidence of adverse events was similar in both treatment arms...